



**Ovarian Cancer
Foundation NZ**

Te Kaikōkiri Mate Pukupuku Kākano-ā-Kopu ki Aotearoa



Annual Report

For the year ended
31 March 2024

Leondra's story

Leondra was diagnosed with stage 3b low-grade serous ovarian cancer in 2017, a disease she had never heard of prior to her diagnosis.

After months of her concerns and symptoms being dismissed and overlooked, she has become a passionate advocate for raising awareness and empowering women to advocate for their own health.

Understanding that change requires a collective effort, Leondra is deeply grateful to supporters of OCFNZ.



Read Leondra's full story here



“

Thank you to everyone who donates, fundraises for and supports OCFNZ. Your contributions make a significant impact for all women living with ovarian cancer.

– **Leondra**

”

A note on terms used:

- ▶ Unless otherwise specified, “ovarian cancer” includes cancer of the fallopian tubes, peritoneum and ovaries.
- ▶ Low-grade serous ovarian cancer may also be referred to as LGSOC in this report
- ▶ The Ovarian Cancer Foundation New Zealand may be referred to as OCFNZ.



ovariancancerfoundation.org.nz



office@ocfnz.org.nz



/ovariancancerfoundationnz



/ovariancancerfoundationnz

Ovarian Cancer Foundation New Zealand

A strong voice for ovarian cancer in New Zealand

In January 2024, we took a bold step in the evolution of our organisation, changing our name to the Ovarian Cancer Foundation New Zealand.

Formerly known as Cure Our Ovarian Cancer, this change is part of a broader strategy to strengthen our presence and impact. Our new name cements our position as a changemaker for ovarian cancer in New Zealand and creates a strong foundation for future growth as we continue working to improve ovarian cancer care in New Zealand.

We are incredibly grateful to Reverend Leo Te Kira for gifting us our Te Reo Māori name: Te Kaikōkiri Mate Pukupuku Kākano-ā-Kopu ki Aotearoa. This translates to “the agents for change for ovarian cancer in Aotearoa,” beautifully capturing our mission and values.

The overwhelming support we’ve received since announcing our new name fills us with pride, and we’re excited for what lies ahead.

Contents

Our new name	2
About the Ovarian Cancer Foundation New Zealand	4
A message from Jane and Alana	5
Our people	7
Breakdown of costs	9
Research	11
Advocacy	13
Awareness and education	15
Support	17
Low-Grade Serous Ovarian Cancer Initiative	19
Fundraising	21
Step Up for Ovarian Cancer	23
Performance report	27

Our vision

For every woman to have the chance to live the life she wants, free from ovarian cancer.

Our mission

To improve ovarian cancer care today, and fund transformational research to find tomorrow's cure.

The reality

Despite our vision, Kiwi women with ovarian cancer face significant challenges throughout their journey. They often encounter disparities in healthcare access compared to those with more common cancers, leaving them underserved and unsupported.

We're committed to changing this

OCFNZ is a nationwide, patient-focused organisation dedicated to driving positive change in the ovarian cancer space. We do this by raising awareness, advocating with women, supporting women facing ovarian cancer, and funding transformational research.

Leading awareness

We spread the word about ovarian cancer and break down the stigma surrounding ovarian cancer. We educate the community and primary care providers on symptoms so that everyone knows what to look out for.

Advocating with women

We amplify the voices of our community to push for faster diagnosis, more funded treatment options, and research funding. We are making sure ovarian cancer receives the attention and resources it deserves.

Facilitating support

We provide support to women navigating their ovarian cancer journey. From diagnosis and treatment to recurrence and beyond, we help women access the resources and support they need at each stage.

Funding research

We fund transformational research, supporting both established and emerging researchers in the ovarian cancer field, with the aim of discovering new breakthroughs and ultimately finding a cure.

Low-Grade Serous Ovarian Cancer Initiative

To honour our organisation's original purpose, we place a special focus on low-grade serous ovarian cancer, establishing pathways for funding for low-grade serous ovarian cancer research globally and providing resources and support for women, through the Low-Grade Serous Ovarian Cancer Initiative.

A message from *Jane and Alana*

On behalf of our team, we want to acknowledge and thank everyone who has supported our mission this year.

Whether through donations, grants, fundraising efforts, or simply sharing our message and being part of our community, your support has made a significant difference.

Reflecting on the past year, we have much to celebrate. It has been a year of laying solid foundations for future growth and developing a robust organisational strategy to define our priorities for the organisation. We've also had our most successful fundraising year to date, an achievement that has positioned us well for further growth in the coming year.

A major highlight was the relaunch of our organisation in January 2024 as the Ovarian Cancer Foundation New Zealand - Te Kaikōkiri Mate Pukupuku Kākano-ā-Kopu ki Aotearoa. This rebrand is more than just a new name; it is a clear statement of our commitment to driving change in the ovarian cancer landscape in New Zealand.

To honour our organisation's original mission and our founder, Jane, we're committed to maintaining a special focus on low-grade

serous ovarian cancer. This year, we began work to establish a distinct identity for this important aspect of our organisation. From September 2024, this work will be known as the Low-Grade Serous Ovarian Cancer Initiative.

One of the most inspiring aspects of the year has been seeing our community come together in impactful ways to show their support for OCFNZ. One notable fundraiser is Team Emma. A portion of their fundraising will fund our first-ever Overseas Travel Grant, to enable an early-career researcher the opportunity to gain valuable experience in an international ovarian cancer research laboratory in late 2024.

Additionally, our annual Step Up for Ovarian Cancer campaign, held during Ovarian Cancer Awareness Month in February, exceeded expectations by raising over \$25,000. We are excited to build on this success and expand the campaign for 2025.

In August, we reached another significant milestone when Jane and Trustee Elizabeth Pennington presented to the Health Select Committee, completing our 2022 National Ovarian Cancer Report - Steps to Change Lives, submission to Parliament. Our ongoing engagement with the government shows our commitment to working together for meaningful change in ovarian cancer care.

We are particularly proud of the continued growth and development of our team. Our Fundraising Manager, Whitney's promotion to General Manager in January 2024 highlights her expertise and leadership. With Whitney and our Operations Coordinator, Holly in place, Jane was able to step back from daily operations and redirect her focus to her key strengths in advocacy and research. We are confident that with this strong team, we are well-positioned to drive our organisation to new heights in the 2025 financial year.

We also want to recognise the important work of other organisations driving change in the cancer space. With one woman dying of ovarian cancer every two days, collaboration is more important than ever!

Finally, we want to acknowledge the courage and resilience of all wāhine affected by ovarian cancer and their whānau. Your bravery is a constant source of inspiration and a powerful reminder of why we do this work.

As we look ahead, we are focused on expanding our programmes with an emphasis on providing more support for women with ovarian cancer. We also aim to deepen our engagement with you, our community, because there is still much to be done to improve ovarian cancer care.

"Thank you for being a part of our incredible community."



Jane Ludemann
Founder and Trustee



Alana Allan
Chairperson

Our people

We're a passionate team, motivated by the resilience and strength of the women we serve. Their stories drive our commitment to improving treatment, care, and support for people living with ovarian cancer.

Our team



Whitney Gernhoefer
General Manager



Holly Townsend
Operations Coordinator



Jane Ludemann
Founder/ Volunteer / Trustee

Our Board of Trustees



Alana Allan – Chairperson
BBus PGDipAppPsych
Elected 2021



Jane Ludemann
BSc BOptom(hons)
Elected 2018



Dr. Ben Russell
PhD (Wool and Animal Science)
Elected 2022



**Learn more
about our team**




Elizabeth Pennington
BA Masters Nursing
Elected 2021



Dr. Alicia Didsbury
PhD (Cancer Immunology)
Elected 2021

The challenges we face



Ovarian cancer is the least survivable women's cancer, and more women die from ovarian cancer than all other gynaecological cancers combined



One woman is diagnosed with ovarian cancer every day

Another woman dies every two days

Women visit their GP on average 3–5 times before being referred for testing



women take **longer than six months** to get a diagnosis from when they first present to their doctor with symptoms



49%

of women are diagnosed through the Emergency Department (ED)



83% one-year survival rate
when diagnosed through a GP

58% one-year survival rate
when diagnosed through ED

36% five-year survival rate



Erin's story

Stage 4 low-grade serous ovarian cancer


Erin spent nearly a year having her symptoms dismissed as constipation or irritable bowel syndrome. Her regular doctor didn't take her seriously, putting symptoms down to IBS, while an ER doctor told her to eat some All-Bran and lose weight to help alleviate her symptoms. After seeking a second opinion, Erin was shocked to learn she had ovarian cancer. Erin is incredibly vocal about her experience, emphasising the importance of trusting your instincts when it comes to health concerns. Her advice to others is to seek a second opinion if you need to and not to feel embarrassed about advocating for your own health.



Read more

Breakdown of costs

We rely on the support of our generous community to help fund our vital services



Volunteer highlight

We're incredibly grateful to Ele for her ongoing support of OCFNZ. Each year, Ele dedicates her time to organise and run a stall at the Wānaka Show, where she raises both funds and awareness about ovarian cancer. Over the years, she has also volunteered her time to speak to local groups about ovarian cancer and is one of our original regular givers. Ele is truly passionate about educating the community on the symptoms of ovarian cancer and helping OCFNZ improve ovarian cancer care in New Zealand.

Thank you, Ele, for your unwavering commitment and support!



Research

Together, we're funding research to discover breakthroughs that improve the lives of women with ovarian cancer.

We fund transformational research, supporting both established and emerging researchers in the ovarian cancer field, with the aim of discovering new breakthroughs and ultimately finding a cure.

This year, we have invested more into ovarian cancer research than ever before. We invited applications for three research grants of \$30,000 each, including two general ovarian cancer research grants and one grant focused on low-grade serous ovarian cancer.

Our grant rounds attracted a record number of applications, and we awarded funding to Helena Abolins-Thompson and Dr Kenny Chitcholtan for their promising research projects.

A third grant was awarded to a New Zealand-based researcher, who was collaborating with a team in Australia. However, the Australian team was unable to secure their share of the funding, which led to the grant remaining unutilised. These funds will be carried over into our next granting round in the next financial year.

We are pleased to continue our partnership with the GRACI Gynaecological Cancer Research Foundation, which administers the grants on our behalf.



Project one

Helena Abolins-Thompson

Investigating chemotherapeutic response in ovarian cancer: generating tumour organoids for wāhine Māori patients.

Helena (Ngāti Toa Rangatira; Kai Tahu) will use tissue from tumour samples taken from wāhine Māori with ovarian cancer, and create living models to expand our knowledge of how ovarian cancer may respond to treatment differently in models from Māori women compared to existing models.

Māori patients are at higher risk of ovarian cancer, presenting at later and more advanced stages. This will allow further exploration into more appropriate and equitable treatments for Māori patient cohorts.



Project two

Dr Kenny Chitcholtan

Validating drug combination efficacy in low-grade serous ovarian cancer using a chicken embryo model.

Dr Chitcholtan will investigate the functions of three recently discovered proteins, using cutting-edge techniques to better understand how they can help treat low-grade serous ovarian cancer.

By uncovering how these proteins work and studying their interactions with the drug combinations, he hopes to develop personalised treatments tailored to individual patients' unique characteristics.

Overseas travel grant

In March 2024, we opened applications for our first overseas travel grant to support an early-career researcher in gaining experience at an international ovarian cancer research laboratory.

The up to \$10,000 grant will allow the recipient to visit one of four renowned laboratories, using OCFNZ's connections with leading researchers in Australia, Canada, the United Kingdom, or the United States.

We are excited about the opportunity to help an emerging researcher advance their knowledge and expertise in the field of ovarian cancer.

Advocacy

Thanks to you, we have a stronger voice when we campaign for better diagnosis, treatment, and care.

We amplify the voices of our community to push for faster diagnosis, more funded treatment options, and research funding. We are making sure ovarian cancer receives the attention and resources it deserves.

Submission to the Health Select Committee

In 2022, we submitted the first-ever National Ovarian Cancer Report – Steps to Change Lives to Parliament, detailing the current state of ovarian cancer in New Zealand and highlighting the immediate actions needed to make improvements.

Key areas for improvement included dedicated funding for research, better access to clinical trials, improvements to how ovarian cancer is diagnosed, and more funded treatments.

In July 2023, we met with the Health Select Committee (HSC) for our oral submission - the final step in this submission process - urging the HSC to adopt our recommendations.

The HSC released their report soon after, acknowledging the issues with the diagnosis, treatment, and research of ovarian cancer.

They made the following two recommendations:

- ▶ They endorsed our recommendation to include ovarian and uterine cancer symptoms education in the National Cervical Screening Programme and strongly encouraged Te Whatu Ora (Health New Zealand) to investigate this option.

- ▶ They encouraged Te Aho o Te Kahu (Cancer Control Agency) to collaborate with other agencies to explore how they can measure the effectiveness of detection, diagnosis, and treatments for ovarian cancer.

We will continue to work with the relevant parties to advocate for the implementation of these recommendations.



My Life Matters

We proudly partnered with Patient Voice Aotearoa and a collective of patient advocate organisations representing one million patients with cancers, rare disorders, and other life-limiting conditions to launch the My Life Matters campaign.

The campaign called for:

- ▶ Increased investment and timely access to medicines to cater to the growing healthcare needs of the New Zealand population, and to keep up with the rest of the OECD.
- ▶ Inclusion of the patient voice in the decision-making processes regarding medicines investment by the New Zealand government.

These issues are especially relevant for our ovarian cancer community, which continues to face challenges in accessing equitable healthcare. This includes limited access to modern medicines, with both Caelyx and Avastin sitting on Pharmac's options for investment list for over a decade. As a result, women with ovarian cancer are often forced to choose between paying for these life-extending drugs, often at a huge personal cost, relocating their families to countries where these treatments are funded, or going without.

We will be participating in the inaugural New Zealand Medicines Summit in April 2024, where members of Parliament, representatives from Pharmac, and patient advocacy organisations will gather to discuss these critical issues.

CANGO

We're proud to be part of the Alliance of Cancer Non-Governmental Organisations (CANGO), advocating with other cancer charities to improve access to new cancer medicines and treatments in New Zealand.

Submissions

In 2023, we submitted in favour of Pharmac retaining rule 8.1b, giving children with cancer access to the best treatment for their cancer. In March 2024, Pharmac announced they would be retaining the rule, meaning that in the rare cases where children are diagnosed with ovarian cancer, they will be able to access the best treatment available.

In February 2024, we made two submissions to Pharmac in relation to funding for two ovarian cancer drugs.

- ▶ We made a submission in support of Pharmac funding Niraparib for the first-line treatment and second-line maintenance treatment of advanced, high-grade serous, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer. Pharmac's decision is due in May 2024.
- ▶ We made a submission strongly protesting Pharmac's proposal to decline funding for bevacizumab in the second-line treatment of high-risk, advanced ovarian cancer. Their decision is due in June 2024.

Awareness and education

Together, we're raising awareness of ovarian cancer, empowering women to recognise symptoms and advocate for their health.

We spread the word about ovarian cancer and break down the stigma surrounding it. We educate the community and primary care providers on symptoms so that everyone knows what to look out for.

Poster series for GPs

In May 2023, we distributed awareness posters highlighting common ovarian cancer symptoms to over 1,200 GP practices nationwide, helping to educate doctors and nurses on symptoms while raising community awareness.

Survivors Teaching Students

In November 2023, our founder Jane shared her ovarian cancer journey with Southern Hospital as part of ANZGOC's Survivors Teaching Students programme. This initiative helps educate future healthcare providers through real-life experiences, offering valuable insight into the patient journey.

World Ovarian Cancer Day

World Ovarian Cancer Day, held annually on 8 May, is an important occasion for raising awareness of ovarian cancer worldwide and reminding women that they are not alone.

This year, we launched campaigns both nationally and at key international locations in collaboration with our Low-Grade Serous Ovarian Cancer Initiative. Featuring Erin, the campaign emphasised the symptoms of ovarian cancer and encouraged women not to dismiss them.



Ruby's story

Stage 3 mucinous ovarian cancer

During her pregnancy, Ruby experienced pain and a growing mass which doctors assured her was unlikely to be cancer. Six weeks after giving birth, the mass ruptured, leading to her ovarian cancer diagnosis. What should have been a joyful time for her family became a difficult journey, however, Ruby remains positive and encourages women to stand up for themselves and advocate for their health.



[Read more](#)



Support for women with ovarian cancer

With your help, we connect women with the support and resources they need.

We provide support to women navigating their ovarian cancer journey. From diagnosis and treatment to recurrence and beyond, we're here for every stage of their diagnosis.

Since 2022, we've been running monthly online peer support groups, enabling women with ovarian cancer to connect, share experiences, and build resilience. Facilitated by counsellor, Lisa Almand, these groups are a safe space for women to uplift and support each other.

We've been working hard this past year to expand our support programme, to make it easier for women to access the support and information they need.

We are thrilled to be launching two new exciting support initiatives in 2024:

- ▶ Funded physical rehabilitation sessions through our friends at PINC & STEEL, using their network of accredited physiotherapists. Launching in April 2024, this programme will provide valuable support for women though.
- ▶ The OCFNZ webinar series, presented by leading experts covering topics like exercise, recurrence, and nutrition to provide women with valuable knowledge and tools. Launching in April 2024, this series is designed to arm women with the knowledge they need to support themselves through their diagnosis.

Lisa Almand,
our peer-support
group facilitator



Chloe's story

Stage 1 endometrioid ovarian cancer

At 32, Chloe collapsed with excruciating abdominal pain, leading to the discovery of a mass on her ovary. She underwent surgery and had to make difficult decisions about her fertility. Now cancer-free, Chloe raises awareness and funds in support of other women living with ovarian cancer.



Read more

Learn more about our support services:

ovariancancerfoundation.org.nz/support/

Low-Grade Serous Ovarian Cancer Initiative

Low-grade serous ovarian cancer (LGSOC) is a rare type of ovarian cancer that disproportionately affects younger women. It is severely under-researched and has no specifically approved FDA treatments.

When our founder Jane was diagnosed with LGSOC in 2017, there was no way to donate or fundraise for LGSOC anywhere in the world. Our organisation (previously known as Cure Our Ovarian Cancer) started as a way to fund LGSOC research to improve survival.

In 2019, we expanded our New Zealand activities to all ovarian cancers, but to honour our original purpose, we retain a special focus on LGSOC, facilitating donations and fundraising for leading LGSOC researchers across five countries and providing information to empower women to make informed decisions about their care.

Australia

In Australia, we partner with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) and their fundraising arm, WomenCan. Our amazing fundraisers raised \$17,711.16 AUD to support their LGSOC research. ANZGOG is currently running a clinical trial called PARAGON II, investigating a novel treatment for LGSOC.

Canada

In Canada, we support Dr Mark Carey's LGSOC research group in partnership with the BC Cancer Foundation. This year, our incredible fundraisers raised \$11,200 CAD supporting their work, including continued research on LGSOC drug resistance, the publication of research on Folate Receptor Alpha (FR-a) expression, which identified a potential new treatment for LGSOC and preparations for participation in the RAMP 301 clinical trial.

New Zealand

Through OCFNZ we fund a low-grade serous ovarian cancer project every year. In 2023 we funded a project to validate a novel drug combination in LGSOC by Dr Kenny Chitcholtan from Otago University.

United Kingdom

In the U.K. we support the work of Professor Charlie Gourley and Dr Robb Hollis, in partnership with the University of Edinburgh. With the support of amazing fundraisers like Catherine, we raised £18,698.46 GBP this year. This funding supports a researcher who is routinely growing ovarian cancer in three dimensions in the laboratory. This will more accurately predict which new drugs and which drug combinations might work best in patients with LGSOC. Along with collaborators in the USA, the University is setting up a clinical trial that will test a number of new therapies in patients with LGSOC. They hope that the work in the lab will help them select the best therapies to study.

United States

We continue to work closely with the American LGSOC charity STAAR Ovarian Cancer. Our valued supporters made \$1,125 USD in donations to STAAR via our website. STAAR Ovarian Cancer supported two research projects this year - "Targeting trametinib-resistant LGSOC by drug repurposing (expanded study)" with MD Anderson Cancer Center, and "Endocrine and mTor Therapy in recurrence LGSOC" with the Stephenson Cancer Center at the University of Oklahoma Health Sciences.

OCFNZ also contributed \$5,000 USD to STAAR's "Voices of LGSOC" project, which allowed the LGSOC community to share their experiences with the FDA and other key stakeholders. The ultimate goal of this project is accelerating drug approval within the US, and globally. With our support, STAAR delivered a strong message that LGSOC needs attention, and advocated for meaningful change.

We are grateful for the ongoing support of Catherine from Limerick, Ireland.

Through fundraising over the last few years, she has raised over €25,000 to support Professor Gourley's research into LGSOC!

Catherine hopes that additional research will lead to a longer life expectancy, allowing her to be here for her kids.

LGSOC Patient Survey

We supported the development and distribution of the first global survey of people living with LGSOC, sponsored by Verastem, which identified valuable insights to better understand, support and highlight the needs of those affected by LGSOC

LGSOC
support and resources

Our online peer-support groups help

600
women
with LGSOC

and

200
of their
family, friends + carers

We added nine new resources to our LGSOC website, including a comprehensive patient guide developed with world experts.

View the resources:
lgsoc.org/resources-and-guides/



Fundraising

Team Emma

In honour of the much-loved Emma, a team of over 20 members (led by her husband Kent, and their children) took on the New York Marathon after months of dedicated fundraising. They organised a trivia night, and their school communities at Scots College and St Mark's School also rallied behind them with their own fundraising efforts.

Together, Team Emma raised over \$65,000 for OCFNZ.



Koji and Tomi

In support of Team Emma, Koji and his son, Tomi each took on personal challenges, all in memory of Emma. Koji committed to the intense Taupō Ironman, while Tomi, full of determination, completed the Weet-Bix Kids TRYathlon.

Their efforts raised \$5,800 – an inspiring tribute to Emma's memory.



Painting for Purpose

In March, Fenyi from Painting for Purpose chose OCFNZ as her charity of the month. She created beautiful artwork and donated 50% of the profits from her sales to OCFNZ, raising \$1,005.



Photo credit:
Big Mountain Photography



Soroptimist International NZ

We are honoured to be one of the charities supported by Soroptimist International NZ as their national project. Their commitment to making a difference in the ovarian cancer space is truly inspiring.

This year, Soroptimist Clubs across the country hosted a range of events – art shows, bake sales, garage sales, movie nights, and World Ovarian Cancer Day breakfasts, raising over \$10,400 for OCFNZ.



Twizel Frocktober

An amazing group of women from Twizel came together in style for Frocktober, donning their best frocks every single day throughout October. Dedicated to raising awareness of ovarian cancer and funds for OCFNZ, they held a number of fundraising activities throughout the month, including a popular fashion show that brought the whole community together.

Thanks to their creativity and the strong support from Twizel locals, they raised an impressive \$9,400.

For every dollar raised



75c goes directly into programmes and services to improve ovarian cancer care.

25c helps us raise the next dollar



Step Up *for* Ovarian Cancer

Step Up for Ovarian Cancer 2024 saw 45 amazing people from across the country come together to step up in support of women with ovarian cancer. From step challenges and scenic hikes to holding bake sales and hosting morning teas and long lunches, our supporters stepped up in creative and meaningful ways, raising over \$25,000 for OCFNZ.

A huge thank you to everyone who took part – and to their amazing communities for supporting them.

Louise's Step Challenge
\$330



*University of Auckland
Team T-Cell Bake Sale*
\$2,566



Bianca's Ladies' Lunch
\$1,250



Heidi's Haircut
\$900



Liz and Charley
\$1,100



Wendy's story

**Stage 3 high-grade
serous ovarian cancer**

As part of Step Up for Ovarian Cancer, Wendy travelled around the South Island with her horse Anmoch and husband Stuart to fundraise and raise awareness of ovarian cancer. Diagnosed in April 2021, Wendy is determined to share her story and educate others on the symptoms. Beginning her trek in Oxford, she rode through 37 towns, often joined by her daughters. Along the way, she handed out ovarian cancer information encouraging women to prioritise their health.

*Wendy's
South Island
Horse Ride*

\$2,200





Thank you to our incredible supporters

On occasion, we rely on the support of volunteers and pro bono services to help us with various projects. Thank you to everyone who has supported the Ovarian Cancer Foundation New Zealand this year.

Anne Reddington

Ele and Grant Ludemann

Erin Bassett

Chloe Adams

Gallaway Cook Allan

GoMedia

Harvie Green Wyatt Chartered Accountants

Leondra Roberts

Lisa Finucane

Ruby Smith

Sharon Fenwick

The Fundraising Agency

Topham Geurin Creative Agency

Wendy Gerritsen

Our amazing fundraisers

Our incredible ovarian cancer community

We would also like to acknowledge the support of our global low-grade serous community and thank those people and organisations who have supported us with various activities this year.

Alex Coppock-Bunce

ANZGOG

BC Cancer Foundation

Brianna Leigh Wagner

Diane Evans

Ellie Habib

Elsa Larsen

Erin Bassett

Gilly McClaren

Kari Neumeyer

Landsec

Leslie Vreeland-Corpe

Liz Miller

Michelle Hill

Silvercast

STAAR Ovarian Cancer

University of Edinburgh

Verastem

Performance Report


Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

Approval of financial report

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

The Trustees are pleased to present the approved financial report, including the historical financial statements of the Ovarian Cancer Foundation New Zealand for the year ended 31 March 2024.

APPROVED



Alana Allan

Chairperson
16 September 2024



Jane Ludemann

Trustee
16 September 2024



Alicia Didsbury

Trustee
16 September 2024



Benjamin Russell

Trustee
16 September 2024



Elizabeth Pennington

Trustee
16 September 2024

Entity information

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

'Who are we?', 'Why do we exist?'

Legal name of entity

Ovarian Cancer Foundation New Zealand

Entity type and legal basis

The Trust was registered as Charitable Trust under the Charitable Trusts Act 1957 on 14th June 2018. The Trust was also registered with the Department of Internal Affairs Services as a Charity on 31st July 2018.

Registration

Charitable Trusts Act Registration Number 2707031
DIA Charities Services Registration Number CC55925
Registration Date 31/07/2018

Entity's purpose or mission

Ovarian Cancer Foundation NZ's purpose is to improve ovarian cancer care in New Zealand by funding transformational research, advocating with women for equitable care, facilitating support for women and raising awareness of ovarian cancer. To honour the initial purpose of the organisation, we retain a special interest in low-grade serous ovarian cancer through our activities.

Entity structure

The Trust operates from Dunedin. The Trust Deed states that there must be between two and eight trustees. The Trust currently has five trustees who constitute the governance board. The existing Trustees have the power to appoint further Trustees from members of the public who have an interest in the Trust's charitable purpose.

The governing body is made up of volunteers, no trustees receive remuneration or a fee.

Main sources of entity's cash and resources

The Trust raises all its funds by way of donations and fundraising from the community and by grants from organisations. All money we receive covers the cost of our services (research, advocacy, support and awareness) as well as our operating costs (general, marketing, fundraising etc).

Main methods used by entity to raise funds

Donations

Donations are received from a variety of sources including:

- ▶ Through our website
- ▶ Directly from individuals, community groups and businesses
- ▶ Fundraising events
- ▶ Grants

Fundraising

Members of our community fundraise on our behalf through a number of fundraising initiatives.

Promotion

Our team and trustees engage with the community through presentations, and we promote our work through social media, our website (ovariancancerfoundation.org.nz) and public facing campaigns.

Postal address

C/- Gallaway Cook Allan, P O Box 143, Dunedin Central, Dunedin 9054

Statement of financial performance

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

'How was it funded?', 'What did it cost?'

Revenue	Note	2024	2023
Donations, fundraising and other similar revenue	1	441,295	320,805
Total revenue		441,295	320,805
Expenses	Note	2024	2023
Advocacy, awareness and support services	2	30,684	8,195
Low-Grade Serous Ovarian Cancer Initiative	2	11,501	–
Expenses related to public fundraising	2	30,114	3,949
Volunteer and employee related costs	2	161,144	36,355
Costs related to providing goods or service	2	32,353	30,266
Research grants	2	91,000	60,715
Other expenses	2	1,229	351
Total expenses		358,026	139,831
Surplus/(deficit) for the Year		83,269	180,974

Statement of financial position

Ovarian Cancer Foundation New Zealand
As at 31 March 2024

'What the entity owns?' and 'What the entity owes?'

Assets	Note	31 MAR 2024	31 MAR 2023
Current assets			
Bank accounts and cash	3	563,680	494,819
Total current assets		563,680	494,819
Non-current assets			
Property, plant and equipment	5	1,229	2,457
Total non-current assets		1,229	2,457
TOTAL ASSETS		564,908	497,276
Liabilities			
Current liabilities			
Creditors and accrued expenses	4	–	918
Grants in advance	4	34,628	49,348
Total current liabilities		34,628	50,266
TOTAL LIABILITIES		34,628	50,266
Total assets less total liabilities (net assets)		530,280	447,010
Accumulated funds			
Accumulated surpluses or (deficits)	6	530,280	447,010
TOTAL ACCUMULATED FUNDS		530,280	447,010

Statement of cash flows

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

'How the entity has received and used cash'

Cash flows from operating activities	2024	2023
Donations, fundraising and other similar receipts	391,847	345,154
Cash receipts from other operating activities	34,728	–
Payments to suppliers	(266,715)	(78,542)
Grants paid	(91,000)	(60,715)
Total cash flows from operating activities	68,861	205,896
Cash flows from investing and financing activities		
Payments to acquire property, plant and equipment	–	(2,808)
Total cash flows from investing and financing activities	–	(2,808)
Net increase/(decrease) in cash	68,861	203,088
Bank accounts and cash		
Opening cash	494,819	291,731
Closing cash	563,680	494,819
Net change in cash for period	68,861	203,088

Statement of accounting policies

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

'How did we do our accounting?'

Basis of preparation

The entity has elected to apply PBE SFR-A (NFP) Public Benefit Entity Simple Format Reporting – Accrual (Not-For-Profit) on the basis that it does not have public accountability and has total annual expenses equal to or less than \$2,000,000. All transactions in the Performance Report are reported using the accrual basis of accounting. The Performance Report is prepared under the assumption that the entity will continue to operate in the foreseeable future.

The Performance Report is presented in New Zealand dollars.

Goods and services tax (GST)

The entity is not registered for GST. Therefore all amounts are stated inclusive of GST (if any).

Income tax

Ovarian Cancer Foundation NZ is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

Bank accounts and cash

Bank accounts and cash in the Statement of Cash Flows comprise cash balances and bank balances (including short term deposits) with original maturities of 90 days or less.

Changes in accounting policies

There have been no changes in accounting policies. Policies have been applied on a consistent basis with those of the previousreporting period.

Notes to the performance report

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2024

1. Analysis of revenue	2024	2023
Donations, fundraising and other similar revenue		
Donations and fundraising	375,827	311,060
Grants	65,368	9,746
Other revenue	100	–
Total donations, fundraising and other similar revenue	441,295	320,805
2. Analysis of expenses		
Advocacy, awareness and support		
Advocacy	5,512	602
Awareness	11,462	1,384
Support	13,711	6,208
Total advocacy, awareness and support	30,684	8,195
LGSOC Initiative		
LGSOC Initiative	11,501	–
Total LGSOC Initiative	11,501	–
Expenses related to public fundraising		
Fundraising	5,085	1,270
Marketing	23,835	1,925
Website	1,195	755
Total expenses related to public fundraising	30,114	3,949

	2024	2023
Volunteer and employee related costs		
General employee and volunteer related expenses	–	187
HR	1,150	5,966
Training & development	78	78
Travel – national	2,836	3,302
Wages	157,080	26,822
Total volunteer and employee related costs	161,144	36,355
Costs related to providing goods or services		
Bank fees	105	164
Administration and overhead costs	(62)	172
Financial reporting costs	2,754	2,466
Fundraising consultancy fees	–	18,400
Insurance	1,294	1,186
Legal expenses	1,923	3,110
Marketing projects	14,500	–
Office expenses	275	1,797
Printing & stationery	–	669
Payment processing fees	7,582	2,302
Projects	1,121	–
Subscriptions	1,199	–
Telephone & internet	1,664	–
Total costs related to providing goods or services	32,353	30,266
Grants		
Research	90,000	60,715
Administration of grant	1,000	–
Total grants	91,000	60,715
Other expenses		
Depreciation	1,229	351
Total other expenses	1,229	351

3. Analysis of assets		
Bank accounts and cash		
Australia	–	126
Canada	3,206	3,206
Europe	178	178
Expenses account	–	1,443
NZ Account	551,598	486,641
Payment processor account	8,685	166
US	13	3,059
Total bank accounts and cash	563,680	494,819

4. Analysis of liabilities	2024	2023
Creditors and accrued expenses		
Creditors and accrued expenses	–	918
Total ceditors and accrued expenses	–	918

Unused donations and grants with conditions		
Grants In advance	34,628	49,348
Total unused donations and grants with conditions	34,628	49,348

5. Plant & equipment	2024	2023
Office equipment		
Office equipment	2,808	2,808
Office equipment – accumulated depreciation	(1,580)	(351)
Total office equipment	1,229	2,457
Total plant & equipment	1,229	2,457

6. Accumulated funds	2024	2023
Accumulated funds		
Opening balance	447,010	266,036
Accumulated surpluses or (deficits)		
Current year earnings	83,269	180,974
Total accumulated surpluses or (deficits)	83,269	180,974
Total accumulated funds	530,280	447,010
Total accumulated funds	530,280	447,010

\$142,169 is being held with the intention of bringing a low-grade serous ovarian cancer clinical trial to New Zealand, when a suitable trial becomes available. This is in keeping with the purpose for which it was raised.

7. Commitments

There are no commitments as at 31 March 2024 (Last year - nil).

8. Contingent liabilities and guarantees

There are no contingent liabilities or guarantees as at 31 March 2024 (Last year - nil).

9. Related Parties	2024	2023
Donations		
Trustees and close family members – donations	122,754	130,500
Total donations	122,754	130,500

The Founder provides services to the Trust at no charge equatable to .5 FTE position.

The Trustees provide their skills and oversight of the Trust at no charge.

The Ludemann family have agreed to donate \$115,000 per annum for 2 years to support the trust in its administration and payroll expenditure for the period January 2023 - January 2025.

10. Events after the balance date

There were no events that have occurred after the balance date that would have a material impact on the Performance Report (Last year - nil).

